Cravath Reps Aptuit In $410M Deal With Catalent
Catalent Pharma Solutions Inc., flush with cash after having jettisoned its pharmaceutical printing business, announced Monday it would pay $410 million in cash for the clinical trial solutions business of Aptuit...To view the full article, register now.
Already a subscriber? Click here to view full article